Monday, November 16, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > CEO Life > Health > Novo Nordisk shares surge after news of weight loss trial success

Novo Nordisk shares surge after news of weight loss trial success

in Health, News
Novo Nordisk shares surge after news of weight loss trial success
Share on LinkedinShare on WhatsApp

Novo Nordisk’s new weight loss drug, amycretin, is showing greater potential than Wegovy for weight loss, as its trial resulted in a 13.1% weight loss for participants after 12 weeks, compared to Wegovy’s 6%. Upon the news, the Danish pharmaceutical company’s shares jumped 8% on Thursday.

Novo Nordisk will began phase II of the trial later this year, with results anticipated in early 2026. The company also reported earlier this week that late-stage trials found that another weight loss drug, Ozempic, decreased the risk of kidney disease progression or death from kidney or cardiovascular complications by 24% in patients with diabetes who also had chronic kidney disease.

“As we always say, safety will be key and Novo are waiting to see results of the subcutaneous formulation before making a clinical plan,” said Yuri Khodjamirian, chief investment officer at Tema ETFs. “Overall, we think this bolsters Novo’s position as it now has several follow up agents to Ozempic/Wegovy, where the patent expires in 2031/32, led by Cagrisema and now Amycretin, to help evergreen their obesity franchise.”

Tags: Novo NordiskOzempicstock marketWegovyWeight loss drugs

Related Posts

To be successful in 2025, a therapist says do these 5 things: It works ‘any time of year’
Health

Why switching off from work is so hard

Trump pardons Founder and former CEO of Binance
News

$1.2 billion in stolen Binance crypto seized by U.S.

U.S. officials order Nvidia to stop sales of AI chips to China
News

Nvidia stock continues to fall following Huang’s resignation

Microsoft outage still affecting millions of users
News

Microsoft outage still affecting millions of users

Nebius secures $3 billion deal with Meta
News

Nebius falls 10% on weak outlook

Siemens CEO says company is ready for tariffs
News

Siemens CEO vows to maintain partnership with Nvidia

Hiring Jensen Huang would be an ‘honor,’ says Musk
News

Hiring Jensen Huang would be an ‘honor,’ says Musk

Barrick CEO says copper remains on a positive trajectory despite 50% tariffs
News

Barrick Mining files for IPO of North American business

Nvidia reveals new H200 chip for AI training
News

Nvidia shares rebound 5% as Huang faces further investigation

CoreWeave and Meta sign $14 billion deal
News

CoreWeave CEO reports ‘breakout’ quarter, shares jump 11%

No Result
View All Result

Recent Posts

  • Yes, the Great Barrier Reef is still a must-see
  • Why switching off from work is so hard
  • The hidden meanings in Hokusai’s iconic Great Wave
  • $1.2 billion in stolen Binance crypto seized by U.S.
  • Nvidia stock continues to fall following Huang’s resignation

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.